Systemic markers of exacerbated chronic obstructive pulmonary disease: How they can help with the decision of whether or not to prescribe antibiotics

Archivos de Bronconeumologia

Volumn 44, Issue 11, 2008, Pages 581-583

  Soler, Néstor ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; CORTICOSTEROID; PEPTIDE; PROADRENOMEDULLIN; PROCALCITONIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CALCITONIN; PROTEIN PRECURSOR;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; EDITORIAL; HUMAN; MORTALITY; SPUTUM CULTURE; SPUTUM VISCOSITY; ACUTE DISEASE; BLOOD; DECISION MAKING; META ANALYSIS; RESPIRATORY TRACT INFECTION;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; DECISION MAKING; HUMANS; META-ANALYSIS AS TOPIC; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 55949114731     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(08)60109-3     Document Type: Editorial

References (13)

1. Christ-Crain M, Müller B. Biomarkers in respiratory infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007;30:556-73.
2. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutiérrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2006;114:894-903.
3. Nseir S, di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M, Soubrier S, et al. Multidrug resistant bacteria in patients with acute severe exacerbations of chronic obstructive pulmonary disease: prevalence, risk factors and outcomes. Am J Respir Crit Care Med. 2006;34:2959-66.
4. Ram F, Rodríguez Roisin R, Granados Navarrete A, García-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Acute Respiratory Infections Group. Cochrane Database Syst Rev. 2006;(2):CD004403.
5. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638-45.
6. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2004;39:980-6.
7. Soler N, Agustí C, Angrill J, Puig de la Bellacasa J, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease (COPD). Thorax. 2007;62:29-35.
8. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Co-peptin, C-reactive protein and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058-67.
9. Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Müller C, et al. Plasma pro-adrenomedullin but not proendothelin predicts survival in exacerbations of COPD. Chest. At press 2008.
10. Weis N, Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 2004;17:88-91.
11. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206-17.
12. Stoltz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonic-guidance with standard therapy. Chest. 2007;131:9-19.
13. Müller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37:145-52.